Although current histopathologic variants do not differ in treatment recommendations, the isocitrate dehydrogenase (IDH)-wildtype glioblastoma, corresponding to the clinically defined primary glioblastoma, is known to have a more aggressive clinical course [10, 12]. This evidence concerns the gene IDH1 and glioblastoma.